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Severe. lifelong, unresolv;ng pyoderma gangrenosum 
occurs in association with recurrent episodes of sterile 
pyoarthrosis and the presence of a serum factor (called 
"streaking leukocyte factor") (1) responsible for en-
hancing random migration of purified human neutrophils 
and mononuclear leukocytes in vitro. Pyoderma gan-
grcnosum is only one feature of this unusual disease. 
Minor trauma of any sort leads to an excessive accu-
mulation of both mononuclear and polymorphonuclear 
leukocytes in tissue. This causes subcutaneous mdura-
tion. stenle abscesses. stertle pyoarthrosls. and exten-
sive areas of skin necrosIs similar to those occurring In 
claSSical pyoderma gangrenosum. except (hat (he Ie· 
sions are larger and more conriuenl. The arthritic Ie· 
sions are characterized by synOVial fluid leukocyte 
counts greater than 100 OOO/mmJ and a severe synovitis 
(1). We describe a patient with the streaking leukocyte 
factor syndrome who has been treated successfully with 
tacrolimus (FK 506. Prograt, Fujisawa Pharmaceutical 
Co •• Osaka. Japan I. 
Case Report 
The pallent was a 31-year-old white man who has had 
a lifelong history of recurrent and chromc stenle ab-
scesses involving the soft tissues. skin. and joints, 
which began in infancy and was shown to be associated 
with "strealung leukocyte factor" in his serum (1). Be-
cause of the hypertrophic and erosive nature of the 
arthntic process. the patient had surgical procedures on 
multiple large Joints. His history IS summarized in Table 
1. The patient was referred to the autOimmune clinic at 
the Universlry of Pittsburgh Medical Center In Apnl 
1991 with a well-established clintcal. histopathologic. 
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Age 11 to 31 
Age 13 
Age 28 
Sterile Pbscess~s at InJecnon sues 
Chronic stenle pyoanhrosls of the left Jnkle 
Chronac stenle pyoanhrosls 01 the ngnt ankle 
Right elbow chronic stenle pyoarthrosls; nght 
hip chronic stcnle anhrosls wHh dislocanon 
Right elbow stcnle pyoanhrosis and chronic leg 
ulceration 
Stenle abscess oi the torehead 
Bilateral massive leg ulceranon 
Recurrent lell Jnd thillh ulceranons as well as 
new ulcer formanon In the pertneum. groin. 
and chest wall 
Severe acne with facial. neck. and chest wall 
ulceranon and scamng 
Sterile pyolnhrosls wHh destruction 01 the right 
elbow and hip 
• Treated slncc that aile Willi pl;umapnc~slp ind dilfe~nl combina-
flons of prednISOne 120 to 110 mJ 0 I. lelra~line 12 g/d I. thalidomide 
IJOO m8ldl. sulfualulfte tJ glOI. Jnd dapsone t200 m8ld). 
,md serologIc diagnOSIs oi this syndrome. Before his 
reierral. he had been treated at Columbia-Presbyterian 
\1edical Cl!nter (New York. New York) and the Na-
tional Institutes of Health with plasmapheresIs. high 
doses of steroids. a wide range oi immunosuppressive 
cytotoxic agents. and thalidomide. but none of these 
treatments yielded a response. 
Laboratory resuhs included nonnal counts and types 
of leukocytes. T cells. and T-cell responses to mitogens: 
a normal nitroblue tetrazolium test: nonnal in-vitro 
phagocytosis of yeast by leukocytes as well as nonnal 
levels of serum immunoglobulins. complement factors 
C 1q • C •• C. C I INH' and total hemolytic complement. 
The laboratory abnormalities the patient had consis-
tently were an anemIa of chroniC disease (hemoglobin. 
'10 to 1:0 g; Ll; an Increased erythrocyte sedimentation 
rate 135 to ~R mlT1Jh): an increased platelet count (350 to 
~:S x I (j"ILl; Increased levels oi a!. a~K and {3 globu-
lins: ;md an Increased complement C, level (:97 to 340 
mgtdL [:.97 to 3.40 gtLIl. 
The hallmark of the disease has been detection of a 
chemokinetic factor to the patient's serum that caused 
Wild random migration oi purified nonnal human neu-
trophils and mononuclear leukocytes by up to 200%. 
which did not IOlIuence chemOtllXls ( 1). This factor has 
continued to be present during a period of 6 years 
despite various therapeutic attempts Isee Table 1). The 
methods used to measure the leukocyte random migra-
[Jon and Isolation of the serum iactor have been prev!-
l)uslv dl!scnbed (I). 
On 9 May 1991. aiter Food and Drug AdmlOlstratlon 
.lnd Local Investigational Review Board approvals (the 
patient gave IOformed consent I, he was started on lac-
rollmus 1 FK 506). a new powerful immunosuopresslve 
macrolide :lntlbiollc 1 :1. He received an oral dose of 
1).15 mgtkg twice dally. T\\elve·hour tacrolimus trough 
plasma levels were measured with an enzyme·linked 
Immunoassay (3). Dose adJuslments were gUided by the 
drug plasma levels. the patient's clinical response (skin 
.lnd JOlOt leSions •• and the biochemical c:vldence of renal 
I nsuthciency (an IOcrease 01 scrum creatinine greater 
I han 2 mgrdLl E~FK Because l.lt the presence 01 a severe. 
disabling osteoporosIs as well as rccurrent venebr:1I 
compression and stress fractures. preexisting steroid 
therapy (20 to 60 mgtd) was rapidly tapered after start-
ing tacrolimus treatment to a sterOid dose of 5 mg orally 
every other day. All other therapeutic agents were dis-
continued before the initiation oi tacrolimus therapy. 
Full dermatologic and medical examinations were 
done at each clinic visit. The assessments made in-
cluded those quantifying pain. subcutaneous induration. 
erythema. cutaneous ulceration. arthritis. and drainage 
from the pyoderma gangrenosum lesions. Renal func-
tion. serum cholesterol. blood glucose. and electrolyte 
levels were also monitored_ 
After 4 weeks. a marked reduction in his pain. lesion 
erythema. ulcer !'ize. and drainage from lesions was 
evident. Complete clinical remission and healing of all 
disfiguring. large open sores was achieved after 12 
weeks of tacrolimus (FK 506) therapy (Figure 1). Tac-
rolimus trough plasma levels were malOtained at high 
levels for the initial 4 weeks 11.5 to 3.8 ngtmLl and 
subsequently at an average of 1.1 ngtmL. A recent 
effort to decrease his tacrolimus dosage resulted in low 
drug plasma levels « 0.7 ngtmLl and a reappearance oi 
focal subcutaneous areas 01 induration. These new le-
sions disappeared completely alter an IOcrease in the 
tacrolimus dose and maintenance of the drug plasma 
trough level at I ngtmL. 
The patient had transient trembling. paresthesias. and 
insomnia with high tacrolimus (FK 506) trough plasma 
levels. These were accompanied by increases in the 
serum creatinine and blood urea mtrogen levels to a 
maximum of 2..t mgldL and 51 mgtdL. respectively. A 
concomitant increase in blood pressure was treated wilh 
a calcium-channel blocker and a beta-adrenergic block-
ing agent. Intermittent hyperkalemia reqUired treatment 
with tiudrocortl50ne acetate 1 Florine!. Bristol-Myers 
Squibb. SomervIlle. New Jerseyl. L:vels of serum cree 
atinine. blood urea nmogen. :.lnd serum potassium have 
~tabilized at 1.9 mgtdL {168 IlmoliU. 2:l mgrdL (10.0 
mmol/Ll. and ~K9 mEq/L fgK~ mmoliU. respectively. 
No clinically slgmficant change has occurred in the lev-
<!Is of blood glucose. cholesterol. or serum trlglycendes. 
For the tirst time slOce birth. the patient does not 
have the skin lesions and the active )OlOt disease. More· 
over. he is now able to resume a full actlviry schedule. 
Six months after the start of tacrolimus I FK 506) treat-
ment. a repeated assay of his serum for the strealc.ing 
leukocyte factor showed an actlv!ry level equal to the 
control serum as well as the buffer solullon. which 
(:oOlalOs 1'1- albumlO and 10% fctal c:lli serum. The 
:lssay mcthod used was Identical to that used before 
tJcrolimus therapy (I). Because a! the IOstablliry of the 
t'Jctor and other logistic proolems. II has not been pos-
~fble to do sequential studies 10 thiS patient to deter-
mine whether va nations 10 the serum :lCtlVlry of the 
c:nhanclOg factor occur at different lacrollmus doses or 
drug plasma levels. 
Disc:ussion 
The streaking leukocyte lactor IS a protelOaceous tac-
tor with a molecular weight 01 160 kd that IS tound In 
(he serum of some pallents with rccurrent stenle ab-
~cesses (I. 5). It is thought to be rcspon!uble for pro-
Flp" 1. Vicer in patllnt wilh Sl"alUnc leukocyte ractor disease. Left. A large necrollc ulcer on the front ot the lower right thigh 
region. RJeht. Marked Improvement and healing of the ulcer was noted durmg 12 weeks ot tacrohmus I FK 506) treatment. 
gresslve destruction and scarring of the skin and joints 
hecause It enhances random mtgration of polymorpho· 
nuclear and mononuclear leukocytes to areas of minor 
trauma. A fatal instance 01 this syndrome has been 
Jescnbed recently (5). 
Although the physical characteristics 01 this protein 
Jre not well known. it is toO small to be an immuno· 
globulin and too large to be a classical cytokine. It is 
probably mutant secretory protem that has an abnormal 
effect on circulating leukocytes. The similarities and 
Jifferences between this abnormal leukocyte·enhancing 
"~treakmg" factor and other chemokinetic factors 
present in normal serum. such as albumm and Icuko· 
kInesls·enhanclng factor. arc descrtbed elsewhere (6). 
The action of this abnormal leukocyte migration factor 
.:an be inhibited partially by contcosterolds and large 
doses of tetracycline, 7-9). The former agents may el-
[her block ItS action at a receptor SHe or. more likely. 
Jirectly modify leukOcyte responses so that they no 
longer react to the factor. TetraCYCline probably acts as 
J nonspeclric Inhibitor 01 protein syntheSIS. limiting the 
production and secretion ot the factor. Neither of these 
.Igents was successlul in controlling the patient's dis· 
case. 
Tacrohmus I FK 506) is a novel macrolide antibiotic 
Isolated from [he SOIl fungus ptreptomvc~s tsukubat!1IS1S 
E~FK The drug has a Wide range of immunosuppressive 
Jctlvltles. because II Inlubits the actlvatlon and prohf· 
erauon of CD4· T·helper lymphocytes (10). The clinical 
experience during the prevIous 3.5 years has shown that 
J high therapeutic index exists for tacrolimus In patients 
who have transplanted organs til) and for pattents with 
either recalcitrant psonasis or pyoderma gangrenosum 
(12. 13). PreVIOusly there were encouraging results 113) 
Jfter treattng pyoderma gangrenosum: therefore. we de-
.:ided to use tacrolimus for our pattent. Interestingly, 
Jfter uSing standard doses of tacrolimus in our patient 
(who had normal hepauc function I. tacroliml!s com-
pletely eliminated the streaking factor from our pa-
tient'S serum. This was associated With complete heal· 
ing. although there IS still scamng of the chrome skin 
ulcers. which had never resolved durmg the preceding 
three decades. 
The speCIfic mode ot action b ... which tacrolimus (FK 
506) might alleViate thiS syndrome IS unclear. However. 
the failure to detect the serum factor after treatment 
,>uggests that HS syntheSIS or release or both was inhib· 
Ited. This probablv re·established the normal phYSlo, 
logic balance between the antagomsltc actlvity of both 
[he leukokinesls-cnhancmg factor and the cell·directed 
IOhibHor to\. Although H IS not known whether taerob-
mus has a direct mhlbitory effect on leukocyte random 
mobility and chemota;os. the d~g appears to have no 
c:tfect on lymphocyte chemoattractant-stlmulated move· 
ment 11·'1. 
The adverse effects caused by tacrolimus (FK 506l 
include impairment of renal function. alteration in glu-
cose homeostasis. and neurotoxicity (4). In our patient. 
the only potentially serious side effects were increases 
in serum creatinine and blood urea nitrogen levels. 
which responded quickly to a dose reduction and sta-
bilized at a slightly increased level. 
Any child with pyoderma gangrenosum. especially at 
sites of recent immunizations (15), may have the 
"streaking leukocyte factor" syndrome. Recognition of 
this potentially fatal syndrome is essential (5), and when 
the condition is unresponsive. treatment with tacrolimus 
(FK 506) should be considered. 
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